Nonetheless, despite the elevated absolute risk of grade 3-4 neutropenia, febrile neutropenia, and severe infections occur in less than 5% of patients and, regardless of the severity of neutropenia, the infectious risk is much lower during neutropenia secondary to CDK4/6 inhibitors than post-chemotherapy. This evidence concerns the gene CDK4 and infection.